为探究 caABMR 移植受者预后与 CD38+ B 细胞浸润关系，研究发现浸润≥93/mm 2 影响移植物存活。 本研究旨在明确被诊断为慢性活动性抗体介导排斥（caABMR）的移植受者中，CD38+ B 细胞浸润与预后之间的关系。研究纳入了 2003 年 4 月至 2021 年 7 月期间经活检证实为 ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma. Preliminary data submitted by Genmab to J&J ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...